menu
    • menu
    [{"orgOrder":0,"company":"Vetter Pharma-Fertigung GmbH & Co","sponsor":"MoonLake Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F","graph1":"Dermatology","graph2":"Phase II","graph3":"Vetter Pharma-Fertigung GmbH & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vetter Pharma-Fertigung GmbH & Co \/ Vetter Pharma International","highestDevelopmentStatusID":"8","companyTruncated":"Vetter Pharma-Fertigung GmbH & Co \/ Vetter Pharma International"}]

    Find Clinical Drug Pipeline Developments & Deals by Vetter Pharma-Fertigung GmbH & Co

    Menu

    Vetter Pharma-Fertigung GmbH & Co

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    SERVICES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vetter Pharma-Fertigung GmbH & Co

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Vetter Pharma-Fertigung GmbH & Co

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sonelokimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Recipient : MoonLake Immunotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            MoonLake Immunotherapeutics Signs Development and Manufacturing Agreement With Vetter Pharma International Gmb...

                            Details : Sonelokimab (M1095), is MoonLake’s investigational Nanobody® designed to treat inflammatory disease by inhibiting the naturally occurring IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation.

                            Brand Name : M1095

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 26, 2022

                            Lead Product(s) : Sonelokimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Recipient : MoonLake Immunotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth